ERR2598332
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 23
- umap1_2d
- -4.843645618
- umap2_2d
- -3.520921353
- umap1_3d
- 3.724991027
- umap2_3d
- 1.623735043
- umap3_3d
- -0.687291767
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.430
- INTERFERON_GAMMA_RESPONSE+0.380
- KRAS_SIGNALING_DN+0.350
- MYOGENESIS+0.320
- INFLAMMATORY_RESPONSE+0.240
- APICAL_SURFACE+0.220
- UV_RESPONSE_DN+0.190
- APICAL_JUNCTION+0.130
- COMPLEMENT+0.120
- ESTROGEN_RESPONSE_EARLY+0.120
Top 10 suppressed
- MYC_TARGETS_V1-0.660
- E2F_TARGETS-0.580
- MYC_TARGETS_V2-0.550
- G2M_CHECKPOINT-0.490
- DNA_REPAIR-0.470
- MTORC1_SIGNALING-0.430
- OXIDATIVE_PHOSPHORYLATION-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.400
- ANGIOGENESIS-0.390
- CHOLESTEROL_HOMEOSTASIS-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_DV86M0Y7 | pilocytic astrocytoma | — | 0.892 |
| 2 | TCGA-55-8513-01A-11R-2403-07 | — | cohortA1 | 0.853 |
| 3 | MDT-AP-1273 | Med | Medulloblastoma | 0.841 |
| 4 | ERR2598293 | fetal | fetal | 0.840 |
| 5 | TCGA-93-A4JP-01A-11R-A24X-07 | — | cohortA1 | 0.838 |
| 6 | BS_2SFTWNVE | Med | Medulloblastoma | 0.826 |
| 7 | TCGA-69-7980-01A-11R-2187-07 | — | cohortA1 | 0.820 |
| 8 | TCGA-O1-A52J-01A-11R-A262-07 | — | cohortA1 | 0.819 |
| 9 | BS_Y7F9E2E9 | low-grade glioma | — | 0.819 |
| 10 | MDT-AP-2047 | Med | Medulloblastoma | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| COMPLEMENT | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |